Company Delivers
Company Secures
Inaugural Enhanced Games Engaged More Than One Billion People Globally
Launched Live Enhanced Platform, Including Athlete Protocol and 11 Rx Products
Second Quarter 2026 Financial Results
For the three months ended
- Revenue of
$17.7 million , primarily reflecting sponsorship revenue recognized in connection with the inaugural Enhanced Games. - Approximately
$32 million of sponsorship contract value2 secured for the inaugural Enhanced Games with company delivering value to sponsors throughout the year with revenue recognition occurring over several quarters - Net Loss of
$61.9 million mostly comprising costs associated with staging the inaugural Enhanced Games, successful IRB clinical trial, de-SPAC merger completion, increased general and administrative expenses from operating as a public company and launching the Company’s direct-to-consumer platform - Adjusted EBITDA¹ loss of
$42.7 million - Cash and cash equivalents of
$19.6 million as ofJune 30, 2026
Business & Operational Highlights
- Hosted the inaugural Enhanced Games in
Las Vegas in a purpose-built arena complex, securing 10 sponsors and$32 million in sponsorship contract value - Athletes achieved 21 personal bests and three world records since inception
- Successfully completed the interventional phase of a first-of-its-kind
Institutional Review Board (IRB)-approved clinical trial in conjunction with the Games - Launched Live Enhanced platform with athlete branded protocol stack and product line including 11 different Rx therapies and two proprietary supplement products
- First Enhanced Breakers event series debuts with a world record performance
- Signed exclusive media rights agreement with Roku delivering the Games to 100 million North American households on leading streaming platform
- Enhanced Games content and press strategy drove considerable brand value at a fraction of the media cost, significantly increasing owned audience (+884%), social engagements (+419%), and video views (+227%) during event period
- Games engaged one billion people globally including four million live views (excluding Roku streaming data) equivalent to a regular season NBA game or episode of
The Tonight Show withJimmy Fallon - Independent media coverage of Enhanced generated 4,000 global stories in publications reaching a combined 16.7 billion unique visitors per month (UVM) with an additional ~932M people watching globally via a broadcast television piece
- Enhanced received prominent Tier I coverage in Vanity Fair, The Economist, Financial Times,
GQ Magazine ,Times London , Der Spiegel and Men’sHealth Magazine to name just a few - A one hour ESPN E:60 documentary aired on the Enhanced Games on
July 2nd
“Six months ago, Enhanced was a privately held startup with a bold idea and a great deal of skepticism aimed at it,” said
The Company’s second quarter results reflect an intentional decision to invest heavily in its inaugural Enhanced Games, as the foundational platform for both its sports business and as a customer acquisition engine for its performance medicine platform. As a result of this investment, Enhanced established extraordinary brand recognition across the globe. In July, the Company expanded its model beyond one tentpole event per year with the Enhanced Breakers Series. The Breakers Series operates at a fraction of the cost of a full Games event, keeping athletes competing, audiences engaged, sponsors interested, and performance medicine in front of the world year-round. The Company’s strategy leverages the Games to acquire global attention, which is sustained quarter-over-quarter by the Enhanced Breakers and additional planned participatory events that are focused on building and strengthening our community. Enhanced is further recognizing an increase in consumer interest in both sports and live entertainment in an increasingly AI driven world, and the Company is positioned to capitalize on these societal developments through event formats such as the Enhanced Breakers series.
In parallel, the Company continues to focus on growing its performance medicine business operated under the brand Live Enhanced. The Company is also evaluating strategic M&A opportunities in addition to strategic partnerships that would accelerate capabilities in its sports, live entertainment and consumer businesses. Management believes a data intelligence layer and community is critical to winning trust with consumers and will continue to promote education and advocacy for performance medicine products to strengthen Enhanced’s flywheel between its sports, live entertainment and consumer businesses.
Second Quarter 2026 Consolidated Results
For the three months ended
Revenue was
Loss from operations was
Net loss was
Adjusted EBITDA¹ was a loss of
Cash used in operating activities was
Cash and cash equivalents were
Liquidity and Capital Resources
As of
Other Matters
Regulatory Engagement
The Company submitted written testimony to the
Strategic Partnerships
The Company has engaged advisors to identify potential acquisitions and partnerships that would accelerate development of its capabilities across sports, live entertainment and consumer, and is concurrently strengthening its
Brand Research Affirmation
In a pre-Games survey of 1,080 respondents conducted by
Notes
(1) Adjusted EBITDA is a non-GAAP financial measure. The definition of Adjusted EBITDA can be found in the Non-GAAP Financial Measures section of this release. A reconciliation of net loss to Adjusted EBITDA for the three and six months ended
(2) Sponsorship contract value represents the aggregate contracted value of sponsorship agreements executed in connection with the inaugural Enhanced Games. Sponsorship contract value is an operating metric and is not a measure of revenue recognized under GAAP. Contracted amounts are recognized as revenue in accordance with ASC 606 over the periods in which the related performance obligations are satisfied, and the amount and timing of revenue recognized will differ from contract value.
(3) The Company manages its business as a single operating and reportable segment operating within an integrated sports, entertainment, and consumer-health ecosystem.
Non-GAAP Financial Measures
The Company refers to certain financial measures that are not recognized under
The Company defines Adjusted EBITDA as net loss excluding income taxes, net interest expense, depreciation and amortization, equity-based compensation, transaction costs, certain legal costs, restructuring and severance charges, and certain other items when applicable.
Enhanced management believes Adjusted EBITDA is useful to investors because it eliminates the significant level of non-cash and non-recurring items, including stock-based compensation and the one-time transaction cost associated with the Business Combination that affect period-over-period comparability.
Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of the Company’s results as reported under GAAP. Some of these limitations are:
- It does not reflect every cash expenditure, future requirements for capital expenditures, or contractual commitments;
- It does not reflect interest expense or the cash requirements necessary to service interest or principal payments on the Company’s obligations;
- Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced or require improvements in the future, and Adjusted EBITDA does not reflect any cash requirement for such replacements or improvements;
- Equity-based compensation is a recurring component of the Company’s compensation programs, and excluding it does not reflect the full cost of retaining personnel; and
- It is not adjusted for all non-cash income or expense items reflected in the Company’s statements of cash flows.
Adjusted EBITDA should not be considered a substitute for the reported results prepared in accordance with GAAP and should not be considered in isolation or as an alternative to net loss as an indicator of the Company’s financial performance, as a measure of discretionary cash available to invest in the growth of its business, or as a measure of cash that will be available to meet its obligations. This non-GAAP financial measure, as determined and presented by the Company, may not be comparable to related or similarly titled measures reported by other companies.
Additional Information
The Company will host a conference call at
Any accompanying materials referenced during the call will be made available on
Website and Social Media Disclosure
Investors and others should note that Enhanced announces material financial and operational information to its investors using press releases,
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s business strategy and plans, future events and event economics, anticipated sponsorship, media rights and other revenue opportunities, the development and monetization of its direct-to-consumer and telehealth platforms, potential acquisitions and partnerships, expectations regarding the regulatory environment, liquidity and capital resources, and anticipated financial and operational performance. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: the Company’s limited operating history and history of operating losses; the Company’s need for additional capital and its ability to obtain financing on acceptable terms or at all; the Company’s ability to stage future events profitably and to secure sponsorship, media rights, ticketing and hospitality revenue on anticipated terms; the Company’s dependence on athlete, clinician, scientific and commercial partners willing to participate in a novel and publicly scrutinized model; changes in, or the Company’s failure to comply with, laws and regulations applicable to performance-enhancing substances, peptides, compounded products, telehealth and direct-to-consumer healthcare; adverse publicity, litigation or regulatory action concerning the Company, its events, its products or its key personnel; risks relating to athlete health and safety and the Company’s medical and clinical protocols; competition in the telehealth, supplement and performance medicine markets, including pricing pressure; the Company’s ability to build consumer and clinician trust and to develop the data capabilities described in this release; the Company’s ability to identify, complete and integrate acquisitions and partnerships; risks relating to conducting operations and clinical activities in international jurisdictions, including geopolitical instability; the Company’s dependence on the continued services of executive management and other key personnel; risks relating to the Company’s recent business combination and status as a newly public company, including its ability to remediate existing material weaknesses and implement and maintain an effective system of internal controls over financial reporting; and other important factors discussed in the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended
About
Condensed Consolidated Balance Sheets (Unaudited) | |||||||
|
| ||||||
ASSETS |
|
|
| ||||
CURRENT ASSETS: |
|
|
| ||||
Cash and cash equivalents | $ | 19,606,246 |
|
| $ | 25,253,578 |
|
Deposit assets |
| — |
|
|
| 597,011 |
|
Deferred offering costs |
| — |
|
|
| 3,987,901 |
|
Contract asset |
| 15,524,405 |
|
|
| — |
|
Prepaid expenses and other assets |
| 2,408,654 |
|
|
| 436,750 |
|
Total current assets |
| 37,539,305 |
|
|
| 30,275,240 |
|
OTHER ASSETS: |
|
|
| ||||
Deposit assets, long-term |
| — |
|
|
| 1,360,004 |
|
Equipment, net |
| 7,793,770 |
|
|
| 433,804 |
|
Intangible assets, net |
| 30,000 |
|
|
| 30,000 |
|
TOTAL ASSETS | $ | 45,363,075 |
|
| $ | 32,099,048 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) |
|
|
| ||||
CURRENT LIABILITIES: |
|
|
| ||||
Simple Agreements for Future Equity | $ | — |
|
| $ | 29,660,667 |
|
Accounts payable and accrued expenses |
| 40,104,305 |
|
|
| 2,991,524 |
|
Deposit liabilities |
| — |
|
|
| 476,253 |
|
Other current liabilities |
| 2,197,595 |
|
|
| 18,896 |
|
Total liabilities |
| 42,301,900 |
|
|
| 33,147,340 |
|
Commitments and contingencies (Note 12) |
|
|
| ||||
STOCKHOLDERS' EQUITY(DEFICIT): |
|
|
| ||||
Class A Common Stock, |
| 12,898 |
|
|
| 10,800 |
|
Class B Common Stock, |
| 25,884 |
|
|
| — |
|
Additional paid-in capital |
| 113,437,497 |
|
|
| 30,981,684 |
|
Accumulated deficit |
| (110,415,104 | ) |
|
| (32,040,776 | ) |
Total stockholders' equity (deficit) |
| 3,061,175 |
|
|
| (1,048,292 | ) |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | $ | 45,363,075 |
|
| $ | 32,099,048 |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | |||||||||||||||
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
|
|
| ||||||||||||
Revenue | $ | 17,700,179 |
|
| $ | — |
|
| $ | 17,702,934 |
|
| $ | — |
|
Operating expenses: |
|
|
|
|
|
|
| ||||||||
Games, athletes and event Operating Costs |
| 52,037,131 |
|
|
| 643,976 |
|
|
| 59,719,058 |
|
|
| 1,742,950 |
|
Selling, general and administrative expenses |
| 16,640,449 |
|
|
| 2,194,116 |
|
|
| 23,840,565 |
|
|
| 4,388,828 |
|
Transaction expenses |
| 10,877,007 |
|
|
| 265,783 |
|
|
| 12,522,367 |
|
|
| 320,156 |
|
Depreciation |
| 69,207 |
|
|
| 995 |
|
|
| 85,868 |
|
|
| 1,193 |
|
Total operating expenses |
| 79,623,794 |
|
|
| 3,104,870 |
|
|
| 96,167,858 |
|
|
| 6,453,127 |
|
Loss from operations |
| (61,923,615 | ) |
|
| (3,104,870 | ) |
|
| (78,464,924 | ) |
|
| (6,453,127 | ) |
Other income (expenses): |
|
|
|
|
|
|
| ||||||||
Interest income and other expense, net |
| (21,283 | ) |
|
| 93,836 |
|
|
| 90,594 |
|
|
| 133,874 |
|
Total other income (expenses), net |
| (21,283 | ) |
|
| 93,836 |
|
|
| 90,594 |
|
|
| 133,874 |
|
Loss before income taxes |
| (61,944,898 | ) |
|
| (3,011,034 | ) |
|
| (78,374,330 | ) |
|
| (6,319,253 | ) |
Net loss and comprehensive loss | $ | (61,944,898 | ) |
| $ | (3,011,034 | ) |
| $ | (78,374,330 | ) |
| $ | (6,319,253 | ) |
Net loss per share, basic and diluted | $ | (0.53 | ) |
| $ | (0.03 | ) |
| $ | (0.69 | ) |
| $ | (0.06 | ) |
Weighted-average shares of common stock, basic and diluted |
| 117,748,175 |
|
|
| 102,206,153 |
|
|
| 112,901,012 |
|
|
| 100,495,425 |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements |
Condensed Consolidated Statements of Cash Flows (Unaudited) | |||||||
| Six Months Ended | ||||||
|
| ||||||
Operating Activities |
|
|
| ||||
Net loss | $ | (78,374,330 | ) |
| $ | (6,319,253 | ) |
Adjustments to reconcile net loss to net cash used in operating activities |
|
|
| ||||
Stock-based compensation expense |
| 8,511,876 |
|
|
| — |
|
Deferred offering cost write off |
| 4,052,804 |
|
|
| — |
|
Shares issued for services in Business Combination |
| 2,066,232 |
|
|
| — |
|
Depreciation expense |
| 85,868 |
|
|
| 1,193 |
|
Changes in operating assets and liabilities |
|
|
| ||||
Accounts payable and accrued expenses |
| 33,509,793 |
|
|
| (1,033,356 | ) |
Deposit liabilities |
| (476,253 | ) |
|
| — |
|
Other current liabilities |
| 2,178,699 |
|
|
| 9,589 |
|
Deposit assets |
| 1,957,015 |
|
|
| (145,000 | ) |
Prepaid expenses and other current assets |
| (17,496,309 | ) |
|
| (19,077 | ) |
Net cash used in operating activities |
| (43,984,605 | ) |
|
| (7,505,904 | ) |
Investing Activities |
|
|
| ||||
Purchases of equipment |
| (5,235,826 | ) |
|
| (19,959 | ) |
Capitalized internal use software |
| (2,210,008 | ) |
|
| — |
|
Net cash used in investing activities |
| (7,445,834 | ) |
|
| (19,959 | ) |
Financing Activities |
|
|
| ||||
Proceeds from issuance of Simple Agreements for Future Equity |
| 10,341,342 |
|
|
| — |
|
Proceeds from issuance of preferred stock and warrants |
| — |
|
|
| 8,961,743 |
|
Proceeds from Warrant exercise |
| — |
|
|
| 2,333 |
|
Proceeds from SPAC transaction |
| 3,038,332 |
|
|
| — |
|
Proceeds from issuance of Private Placement |
| 24,999,991 |
|
|
| — |
|
Stock-subscription deposit of Private Placement |
| 8,499,950 |
|
|
| — |
|
Proceeds from working capital note |
| 11,750,000 |
|
|
| — |
|
Principle repayment of working capital note |
| (11,750,000 | ) |
|
| — |
|
Payment of offering costs |
| (1,096,508 | ) |
|
| — |
|
Net cash provided by financing activities |
| 45,783,107 |
|
|
| 8,964,076 |
|
(Decrease) Increase in cash and cash equivalents |
| (5,647,332 | ) |
|
| 1,438,213 |
|
Cash and cash equivalents, at beginning of period |
| 25,253,578 |
|
|
| 4,018,226 |
|
Cash and cash equivalents, at end of period | $ | 19,606,246 |
|
| $ | 5,456,439 |
|
|
|
|
| ||||
Supplemental disclosures of non-cash activities: |
|
|
| ||||
Conversion of Simple Agreements for Future Equity to common stock | $ | 40,002,009 |
|
| $ | — |
|
Offering costs included in accounts payable and accrued expenses |
| 4,071,580 |
|
|
| — |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements |
Non-GAAP Financial Measures | |||||||||||||||
Reconciliation of Net Loss to Adjusted EBITDA | |||||||||||||||
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
|
|
| ||||||||||||
Reconciliation of Net Loss to Adjusted EBITDA |
|
|
|
|
|
|
| ||||||||
Net loss | $ | (61,944,898 | ) |
| $ | (3,011,034 | ) |
| $ | (78,374,330 | ) |
| $ | (6,319,253 | ) |
Interest expense, net |
| 39,101 |
|
|
| (84,293 | ) |
|
| (96,077 | ) |
|
| (111,016 | ) |
Depreciation |
| 69,207 |
|
|
| 995 |
|
|
| 85,868 |
|
|
| 1,193 |
|
Equity-based compensation expense (1) |
| 7,784,404 |
|
|
| — |
|
|
| 8,511,876 |
|
|
| — |
|
Transaction costs (2) |
| 10,877,007 |
|
|
| 265,783 |
|
|
| 12,522,367 |
|
|
| 320,156 |
|
Certain legal costs (3) |
| 193,140 |
|
|
| 126,856 |
|
|
| 733,456 |
|
|
| 291,866 |
|
Restructuring and severance (4) |
| 276,667 |
|
|
| — |
|
|
| 373,999 |
|
|
| — |
|
Other adjustments (5) |
| (17,816 | ) |
|
| (9,543 | ) |
|
| 5,483 |
|
|
| (22,858 | ) |
Total Adjusted EBITDA | $ | (42,723,188 | ) |
| $ | (2,711,236 | ) |
| $ | (56,237,358 | ) |
| $ | (5,839,912 | ) |
Net loss margin |
| (350.0 | )% |
|
| n/a |
|
|
| (442.7 | )% |
|
| n/a |
|
Adjusted EBITDA margin |
| (241.4 | )% |
|
| n/a |
|
|
| (317.7 | )% |
|
| n/a |
|
The Company began presenting Adjusted EBITDA in connection with the Business Combination and its NYSE listing |
(1) Equity-based compensation expense consists of employee and non-employee stock-based compensation. |
(2) Transaction costs consist of offering costs, banking and investor relations fees, other consulting, legal fees, and accounting and tax fees incurred in connection with the Business Combination and related financing activities. |
(3) Certain legal costs for trademark and |
(4) Restructuring and severance consists of severance costs. |
(5) Other adjustments consist of certain non-operating items, including changes in the fair value of SAFEs, unrealized and realized gains and losses, and other miscellaneous items. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260813331607/en/
Investor Contact
enhanced@icrinc.com
Media Contact
media@enhanced.com
Source: